Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 23Radiotherapy 10Magnetic Resonance Spectroscopy 10Radiation 8Specimen Handling 7Lomustine 4Bevacizumab 4Nivolumab 3Biopsy 3veliparib 2trametinib 2olaparib 2lutetium Lu 177 dotatate 2dabrafenib 2cemiplimab 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Photons 2Palliative Care 2Ipilimumab 2D2C7-(scdsFv)-PE38KDEL 2CTLA-4 Antigen 2Aminolevulinic Acid 2vocimagene amiretrorepvec 1varlilumab 1ulixertinib 1tinostamustine 1temsirolimus 1senicapoc 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × AZD1390 × 30 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡